logo
  

Astellas Pharma Submits Fezolinetant NDA To FDA

Astellas Pharma Inc. said that it has submitted new drug application for fezolinetant to the U.S. Food and Drug Administration.

Fezolinetant is an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms or VMS associated with menopause.

VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.

The company noted that it is reviewing the financial impacts of the submission for the fiscal year ending March 31, 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Russia's manufacturing activity grew at the fastest pace in three-and-a-half years in September, supported by increases in production and new orders, survey data from S&P Global showed on Monday. The factory Purchasing Managers' Index posted 52.0 in September, up from 51.7 in August. A score above... India's manufacturing sector growth slowed moderately in September but the overall growth remained robust, survey data published by S&P Global showed on Monday. The manufacturing Purchasing Managers' Index fell to 55.1 in September from 56.2 in August. The score was also below economists' forecast... Final manufacturing Purchasing Managers' survey results from the euro area and the UK are the major reports due on Monday. At 2.30 am ET, the Federal Statistical Office is scheduled to issue Swiss consumer price data for September. Inflation is forecast to remain unchanged at 3.5 percent.
Follow RTT